Medical policy
Tobramycin/loteprednol etabonate (Zylet) Ophthalmic Suspension for Individual…
Cigna medical policy IP0474 · Jan 1, 2023
Key facts
| Policy title | Tobramycin/loteprednol etabonate (Zylet) Ophthalmic Suspension for Individual and Family Plans |
|---|---|
| Insurer | Cigna |
| Policy number | IP0474 |
| Policy date | Jan 1, 2023 |
| Current policy | Yes |
| Insurer page | static.cigna.com |
At a glance
- None 510(k)s referenced
- None PMAs referenced
- None De Novos referenced
- None Clinical trials referenced
- None Articles referenced
- None UDI devices referenced
- None NDC products referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Insurer medical policies
Insurer clinical and medical policies state when a payer covers a device, drug or procedure. Orca1 links each policy to the FDA submissions, trials and articles it cites. Policy text is not reproduced here.
Source: Health insurer clinical and medical policies (insurer as listed); cross-links by Orca1